Emergent BioSolutions Inc
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
EBS$6.05-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets—March and December 31,
ITEM 1. FINANCIAL STATEMENTS
Condensed Consolidated Balance Sheets
(in millions, except per share amounts)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $78.5 | $111.7 |
| Restricted cash | 0.5 | — |
| Accounts receivable, net | 233.5 | 191.0 |
| Inventories, net | 333.4 | 328.9 |
| Prepaid expenses and other current assets | 36.5 | 47.9 |
| Total current assets | 682.4 | 679.5 |
| Property, plant and equipment, net | 379.4 | 382.8 |
| Intangible assets, net | 550.4 | 566.6 |
| Other assets | 191.4 | 194.3 |
| Total assets | $1,803.6 | $1,823.2 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $100.2 | $112.2 |
| Accrued expenses | 14.3 | 18.6 |
| Accrued compensation | 42.0 | 74.1 |
| Debt, current portion | 459.2 | 413.7 |
| Other current liabilities | 14.5 | 32.7 |
| Total current liabilities | 630.2 | 651.3 |
| Debt, net of current portion | 446.7 | 446.5 |
| Deferred tax liability | 34.8 | 47.2 |
| Other liabilities | 28.0 | 28.9 |
| Total liabilities | 1,139.7 | 1,173.9 |
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value per share; 15.0 shares authorized, no shares issued or outstanding | — | — |
| Common stock, $0.001 par value per share; 200.0 shares authorized, 58.0 and 57.8 shares issued; 52.4 and 52.2 shares outstanding, respectively | 0.1 | 0.1 |
| Treasury stock, at cost, 5.6 and 5.6 common shares, respectively | (227.7) | (227.7) |
| Additional paid-in capital | 909.8 | 904.4 |
| Accumulated other comprehensive loss, net | (5.5) | (5.7) |
| Accumulated deficit | (12.8) | (21.8) |
| Total stockholders’ equity | 663.9 | 649.3 |
| Total liabilities and stockholders’ equity | $1,803.6 | $1,823.2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.